OraSure Stock (NASDAQ:OSUR)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$4.19

52W Range

$2.08 - $4.33

50D Avg

$3.37

200D Avg

$2.96

Market Cap

$287.79M

Avg Vol (3M)

$618.16K

Beta

1.01

Div Yield

-

OSUR Company Profile


OraSure Technologies, Inc. and its affiliates are a global leader in the development, production, and commercialization of advanced oral fluid diagnostic solutions and specialized specimen collection tools, serving markets across the United States, Europe, and other international regions. The company operates through two primary divisions: Diagnostics and Molecular Solutions. Its diverse Diagnostics portfolio features a range of crucial offerings, such as the InteliSwab rapid tests for COVID-19 (including professional and prescription versions). It also provides several OraQuick rapid tests, encompassing solutions for HIV (Rapid, In-Home, and Self-Test versions), Hepatitis C (HCV rapid antibody), and Ebola (rapid antigen). Further diagnostic tools include the OraSure oral fluid collection device, utilized for HIV-1 antibody screening and confirmation; the Intercept drug testing systems; various immunoassay tests and reagents; and the Q.E.D. saliva alcohol test. Within its Molecular Solutions segment, OraSure offers an array of genomic products, notably under the Oragene and ORAcollect brand names, alongside specialized microbiome collection solutions and comprehensive GenoFIND genomics laboratory services. The company also supplies collection devices like ORAcollect, RNA, OMNIgene, and RAL, specifically designed for COVID-19 molecular testing. Another key offering is the Colli-Pee device, engineered for the precise volumetric collection of first-void urine. Furthermore, OraSure produces and distributes advanced kits for the collection, stabilization, transportation, and storage of genetic material samples, critical for molecular testing in diverse fields such as academic research, commercial applications (including ancestry, disease risk management, lifestyle analysis), and animal testing. Complementing these, it also provides various other diagnostic tools, including immunoassays and in vitro diagnostic tests. OraSure's sophisticated products and services are distributed to a wide array of clients, including clinical laboratories, hospitals, clinics, various community and public health organizations, wholesale distributors, governmental bodies, medical practices, and a broad spectrum of commercial and industrial entities. Established in 2000, OraSure Technologies, Inc. maintains its corporate headquarters in Bethlehem, Pennsylvania.

Show More

Industry

Medical - Instruments & Supplies

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

501

IPO Date

Nov 17, 1986

Website

OSUR Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 25Dec 24Dec 23
Other Revenues$5.97M$1.22M$3.25M
Product And Services$109.06M$184.61M$402.22M

Fiscal year ends in Dec 25 | Currency in USD

OSUR Financial Summary


Dec 25Dec 24Dec 23
Revenue$115.02M$185.83M$405.47M
Operating Income$-68.12M$-20.60M$54.08M
Net Income$-68.73M$-19.50M$53.66M
EBITDA$-56.74M$-9.73M$73.98M
Basic EPS$-0.94$-0.26$0.73
Diluted EPS$-0.94$-0.26$0.72

Fiscal year ends in Dec 25 | Currency in USD

Latest Earnings Call Transcripts


Q1 26May 06, 26 | 12:00 AM
Q4 25Feb 25, 26 | 5:00 PM
Q3 25Nov 05, 25 | 5:00 PM

Peer Comparison


TickerCompany
NTHINeonc Technologies Holdings, Inc.
STIMNeuronetics, Inc.
NYXHNyxoah S.A.
GNFTGenfit S.A.
PREPrenetics Global Limited
TARAProtara Therapeutics, Inc.
CATXPerspective Therapeutics, Inc.
NAUTNautilus Biotechnology, Inc.
PROFProfound Medical Corp.
UTMDUtah Medical Products, Inc.